Wei Dai1, Junhong Wu1, Xiaopeng Peng1, Wen Hou1, Hao Huang1, Qilai Cheng1, Zhiping Liu2, Walter Luyten3, Liliane Schoofs3, Jingfeng Zhou4, Shenglan Liu1. 1. School of Pharmacy, Gannan Medical University, Ganzhou, Jiangxi, China. 2. Center for Immunology, Gannan Medical University, Ganzhou, Jiangxi, China. 3. Department of Biology, KU Leuven, Leuven, Belgium. 4. Department of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center, Shenzhen, China.
Abstract
BACKGROUND: Hepatic metastasis is the primary and direct cause of death in individuals with colorectal cancer (CRC) attribute to lack of effective therapeutic targets. The present study aimed to identify potential druggable candidate targets for patients with liver metastatic CRC. METHODS: The transcriptional profiles of super-enhancers (SEs) in primary and liver metastatic CRC were evaluated in publicly accessible CRC datasets. Immunohistochemistry of human CRC tissues was conducted to determine the expression level of CDK12. Cellular proliferation, survival and stemness were examined upon CDK12 inhibition by shCDK12 or a selective CDK12 inhibitor named SR-4835 with multiple in vitro and in vivo assays. RNA sequencing and bioinformatics analyses were carried out to investigate the mechanisms of CDK12 inhibition in CRC cells. RESULTS: We identified CDK12 as a driver gene for direct hepatic metastasis in CRC. Suppression of CDK12 led to robust inhibition of proliferation, survival and stemness. Mechanistically, CDK12 intervention preferentially repressed the transcription of SE-associated genes. Integration of the SE landscape and RNA sequencing, BCL2L1 and CCDC137 were identified as SE-associated oncogenic genes to strengthen the abilities of cellular survival, proliferation and stemness, eventually increasing liver metastasis of CRC. CONCLUSIONS: Our data highlight the potential of CDK12 and SE-associated oncogenic transcripts as therapeutic targets for patients with liver metastatic CRC.
BACKGROUND: Hepatic metastasis is the primary and direct cause of death in individuals with colorectal cancer (CRC) attribute to lack of effective therapeutic targets. The present study aimed to identify potential druggable candidate targets for patients with liver metastatic CRC. METHODS: The transcriptional profiles of super-enhancers (SEs) in primary and liver metastatic CRC were evaluated in publicly accessible CRC datasets. Immunohistochemistry of human CRC tissues was conducted to determine the expression level of CDK12. Cellular proliferation, survival and stemness were examined upon CDK12 inhibition by shCDK12 or a selective CDK12 inhibitor named SR-4835 with multiple in vitro and in vivo assays. RNA sequencing and bioinformatics analyses were carried out to investigate the mechanisms of CDK12 inhibition in CRC cells. RESULTS: We identified CDK12 as a driver gene for direct hepatic metastasis in CRC. Suppression of CDK12 led to robust inhibition of proliferation, survival and stemness. Mechanistically, CDK12 intervention preferentially repressed the transcription of SE-associated genes. Integration of the SE landscape and RNA sequencing, BCL2L1 and CCDC137 were identified as SE-associated oncogenic genes to strengthen the abilities of cellular survival, proliferation and stemness, eventually increasing liver metastasis of CRC. CONCLUSIONS: Our data highlight the potential of CDK12 and SE-associated oncogenic transcripts as therapeutic targets for patients with liver metastatic CRC.
Authors: Edmond Chipumuro; Eugenio Marco; Camilla L Christensen; Nicholas Kwiatkowski; Tinghu Zhang; Clark M Hatheway; Brian J Abraham; Bandana Sharma; Caleb Yeung; Abigail Altabef; Antonio Perez-Atayde; Kwok-Kin Wong; Guo-Cheng Yuan; Nathanael S Gray; Richard A Young; Rani E George Journal: Cell Date: 2014-11-06 Impact factor: 41.582
Authors: Pratiksha I Thakore; Anthony M D'Ippolito; Lingyun Song; Alexias Safi; Nishkala K Shivakumar; Ami M Kabadi; Timothy E Reddy; Gregory E Crawford; Charles A Gersbach Journal: Nat Methods Date: 2015-10-26 Impact factor: 28.547
Authors: Prashanthi Ramesh; Tamsin R M Lannagan; Rene Jackstadt; Lidia Atencia Taboada; Nico Lansu; Pratyaksha Wirapati; Sander R van Hooff; Danielle Dekker; Jessica Pritchard; Aleksandar B Kirov; Sanne M van Neerven; Sabine Tejpar; Geert J P L Kops; Owen J Sansom; Jan Paul Medema Journal: Cell Death Differ Date: 2021-06-11 Impact factor: 15.828